Loved ones, caregivers and supporters of Wyomingites living with Alzheimer’s disease will join together Saturday, Aug. 23, ...

Over 580,000 VOQUEZNA® prescriptions filled to date, reflecting 49% growth since last earnings reportNet revenues of $39.5 million reported for Q2Full-year 2025 revenue guidance of $165 million to ...

Discover key insights from Supernus Pharmaceuticals' Q2 2025 earnings, including revenue growth, new product launches, the Sage Therapeutics ...

Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025.

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Revenue (GAAP) surged to $31.7 million, exceeding analysts’ expectations by 88.8% driven by strong ZURZUVAE growth. Net loss (GAAP) narrowed to $49.7 million. This revenue surge, exceeding analysts’ ...

In the preceding three months, 8 analysts have released ratings for Biogen BIIB -0.98% Get Free Report , presenting a wide ...

Supernus Pharmaceuticals has acquired Sage Therapeutics, strengthening its neuropsychiatry product portfolio. In June 2025, ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Biogen BIIB reported second-quarter 2025 adjusted earnings per share (EPS) of $5.47, which significantly beat the Zacks ...

Biogen (NASDAQ:BIIB) traded ~8% higher in the premarket on Thursday after the company posted better-than-expected financials ...

Analysts have given Biogen a total of 11 ratings, with the consensus rating being Outperform. The average one-year price target is $187.27, indicating a potential 46.42% upside.